Glytec LLC Release: Grady Health System Improves Diabetes Care With The Company’s eGlycemic Management System

Glytec’s system for personalized diabetes therapy management translates to better quality of care at Atlanta’s Grady Health System.

WALTHAM, Mass.--(BUSINESS WIRE)--In its quest to ensure high quality care for critically ill patients, Atlanta’s Grady Health System has implemented the evidence-based Glytec eGlycemic Management System^® (eGMS^®), a personalized diabetes therapy management solution.

“We are truly honored to work with Dr. Umpierrez and excited to embark on multiple new studies that further examine the quality, safety and financial implications of glycemic management”

Studies conducted by Emory School of Medicine Professor and Grady Chief of Diabetes and Endocrinology, Dr. Guillermo Umpierrez, show that by using eGMS^®, physicians are able to significantly lower the rate of hypoglycemia (GLUCO-CABG Trial,* Diabetes Care 2015). In addition, studies show that intensive glucose control leads to decreased resource utilization and hospitalization costs.

“Our rate of hypoglycemia among critically ill patients was not at a level we were comfortable with,” said Dr. Robert Jansen, Grady’s Chief Medical Officer and Chief of Staff. “As we worked to improve our care model, the clinical research conducted by Dr. Umpierrez using the Glytec system showed that the system has real merit. We were unanimous in our decision to use eGMS^®.”

With its Level 1 Trauma Center, verified Burn Center, certified Comprehensive Stroke Center and top-rated Cardiac Center, Grady is a destination for many of Georgia’s most complex cases. eGMS^® is currently deployed across all critical care areas -- each assigned an interdisciplinary team of pharmacy, medical and nursing staff to provide localized glycemic governance.

eGMS^® is seamlessly integrated with Grady’s Epic electronic medical record (EMR), allowing users direct access from a patient’s chart without the need for a separate login. Included in eGMS^® are modules for personalized insulin dosing (Glucommander™), blood glucose check alerts (GlucoView^®), and robust analytics (GlucoMetrics^®). Also included is a module, GlucoSurveillance^®, which the hospital relies on for rapid identification of patients in need of insulin therapy. GlucoSurveillance^® interfaces with Grady’s laboratory information system to perform continuous real-time surveillance of blood glucose values, flagging patients who meet pre-defined criteria for persistent hyperglycemia.

Additionally, Glytec is poised to enhance its research partnership with Grady’s Clinical Research Network. “We are truly honored to work with Dr. Umpierrez and excited to embark on multiple new studies that further examine the quality, safety and financial implications of glycemic management,” said Raymie McFarland, Vice President Quality Initiatives at Glytec.

* Gluco-CABG Trial is an investigator-initiated study supported by grants from the American Diabetes Association (7-03-CR-35) and the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources (UL1 RR025008).

About Glytec

Founded in 2006, Glytec is a leading innovator in personalized diabetes therapy management, pioneering the way hospitals and health systems use technology to ensure optimal glucose control and reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The company’s comprehensive eGlycemic Management System^® (eGMS^®) centers on the only FDA-cleared insulin dosing solution able to support intravenous and subcutaneous therapy for adult and pediatric populations across the entire care continuum. eGMS^® integrates seamlessly with EMR systems and connected devices for streamlined use in inpatient and outpatient settings, with the unique ability to support at-home, prescriber-directed care managed through telehealth, population health and other value-based programs. eGMS^® employs a cloud-hosted software-as-a-service (SaaS) model, allowing for rapid implementation and anytime, anywhere access. Efficacy of eGMS^®, including its ability to substantively improve clinical and financial outcomes, has been validated by more than 55 research studies. Results have included dramatic reductions in length of stay, readmissions and A1c levels. Glytec currently holds six U.S. and two international patents, and has more than 50 patents pending. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information, visit www.glytecsystems.com.

About Grady Health System

Grady Health System is one of the largest safety-net health systems in the United States. Grady consists of the 953-bed Grady Memorial Hospital, six neighborhood health centers, Crestview Health & Rehabilitation Center, and Children’s Healthcare of Atlanta at Hughes Spalding, which is operated as a Children’s affiliate. With its nationally acclaimed emergency medical services, Grady has the premier Level I trauma center in the Metro Atlanta region and serves as the 911 ambulance provider for the city of Atlanta. Grady’s American Burn Association/American College of Surgeons verified Burn Center is one of only two in the state. And the Marcus Stroke and Neuroscience Center is a Joint Commission designated Advanced Comprehensive Stroke Center. Other key services include Grady’s Regional Perinatal Center with its Neonatal Intensive Care Unit, Georgia’s first Cancer Center for Excellence, The Avon Breast Health Center, the Georgia Comprehensive Sickle Cell Center, and the Ponce de Leon Center – one of the top three HIV/AIDS outpatient clinics in the country.